AKI	acute kidney injury
ARC	augmented renal clearance
AUC	area under the concentration time curve
BLBLI	β-lactam/β-lactamase inhibitors
BLI	β-lactamase inhibitors
BMI	body mass index
CAZ/AVI	ceftazidime/avibactam
CFR	cumulative fraction of response
CFU	colony-forming units
C.I	continuous infusion
CL	clearance
Cmax	maximum concentration
Cmin	minimal concentration
CrCL	creatinine clearance
CRRT	continuous renal replacement therapy
CT	threshold of concentration
C/T	ceftolozane/tazobactam
CVVH	continuous venovenous hemofiltration
CVVHD	continuous venovenous hemodialysis
CVVHDF	continuous venovenous hemodiafiltration
ECMO	extracorporeal membrane oxygenation
E.I	extended infusion
g	gram
h	hour
ICUs	intensive care units
IMI/REL	imipenem/relebactam
LD	loading dose
MDR	multidrug-resistant
MEV	meropenem/vaborbactam
MIC	minimum inhibitory concentration
MRSE	methicillin-resistant S. epidermidis
PICO	population, intervention, comparator, outcome
PIRRT	prolonged intermittent renal replacement therapy
PK/PD	pharmacokinetic/pharmacodynamic
PsA	Pseudomonas aeruginosa
PTA	probability of target attainment
Qxh	every x hours
RRT	renal replacement therapy
TDM	therapeutic drug monitoring
VA-ECMO	venoarterial ECMO
Vd	volume of distribution
VV-ECMO	venovenous ECMO
%ƒT > MIC	percentage of free drug concentration above MIC